The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Performance was driven by a diversified model where strong operating company results were bolstered by a significant Wi-Fi 6 licensing settlement.

Management emphasizes compounding long-term intrinsic value per share through disciplined capital allocation rather than maximizing short-term earnings.

Benchmark's record revenue was supported by the successful commencement of production from the Cherokee development, which performed in line with expectations.

Deflecto is undergoing structural manufacturing optimization and restructuring to position the platform for profitable growth as demand improves.

The Intellectual Property platform has been aggressively rationalized to align its cost structure with the episodic nature of licensing opportunities.

Acacia maintains a debt-free parent company balance sheet, which management views as a critical competitive advantage for executing acquisitions during market dislocations.

The acquisition pipeline remains active, with management focusing on bilateral discussions and acute situations rather than broad, competitive auction processes.

Benchmark's strategy prioritizes maximizing long-term value over near-term production, with plans to evaluate additional drilling units using a disciplined underwriting framework.

Deflecto is positioned for meaningful operating leverage as market demand recovers, supported by implemented structural cost improvements.

Acacia is exploring a potential transaction to gain direct ownership in Mycovia Pharmaceuticals, aiming for greater participation in value creation following upcoming FDA milestones.

The company continues to utilize its public securities portfolio as a 'toehold' strategy to deepen diligence on potential strategic acquisition targets.

Recorded a $3.7 million non-recurring legal expense related to a legacy litigation matter, which management believes is substantially complete and potentially recoverable.

Recognized a full write-down of the investment in MalinJ1 due to liquidity issues at Mycovia Pharmaceuticals following an extended FDA readout timeline.

Licensing revenue of $60.6 million was subject to significant contractual splits with partners and contingency counsel, particularly as the TP-Link case proceeded late into the court system.

Amortization of legacy intangible assets has declined significantly and is expected to remain at a lower run rate through next year.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management confirmed the Q2 results included a full quarter of production from the first wholly owned operated well.

The team has advanced work on creating several units for future drilling, typically aiming for one producing well per unit to create offsetting value in proved undeveloped reserves (PUDs).

Future wells are being underwritten to type curves similar to the performance of the initial Cherokee well.

Management views strong earnings from Class A trucking firms as an attractive leading indicator, though Deflecto's numbers haven't reflected this yet due to existing OEM inventory levels.

As existing inventory works through the system, Deflecto is expected to benefit from incremental manufacturing volumes.

Deal flow is currently at its strongest level, driven by private equity assets reaching maturity and private credit lenders seeking exits from specific businesses.

Acacia is avoiding broad auctions, focusing instead on bilateral discussions where they can leverage operational expertise and certainty of outcome.

The $60.6 million licensing settlement was booked as accounts receivable at the end of Q2, with the cash actually received in Q3.

Management noted that EBITDA is not a perfect proxy for cash in this segment due to the $3.7 million legacy legal expense and high contingency fees for cases that go deep into the litigation process.